Estenova aims to become a big name in medical aesthetics
The Chinese developer of anti-wrinkle fillers is seeking a cash injection from a Hong Kong share listing to bring its plumping products to the market Key Takeaways: The biotech made…
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting from its…
BeiGene celebrates profit milestone on soaring drug sales
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
RNA drug developer Ribo Life targets fresh funding channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
Neautus looks outward to boost its traditional medicine story
The maker of traditional Chinese medicines has applied for a Hong Kong IPO after abandoning two listing attempts on China’s domestic A-share market Key Takeaways: Neautus has applied to list…
Recent Articles
BRIEF: Weibo profit doubles as AI search gains traction
9898.HK
WB.US
BRIEF: Tuya swings to profit as premium client base expands
2391.HK
TUYA.US
RECENT ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
